These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17198925)

  • 1. Adiponectin and chronic kidney disease.
    Guebre-Egziabher F; Drai J; Fouque D
    J Ren Nutr; 2007 Jan; 17(1):9-12. PubMed ID: 17198925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should we quantify insulin resistance in patients with renal disease?
    Shen Y; Peake PW; Kelly JJ
    Nephrology (Carlton); 2005 Dec; 10(6):599-605. PubMed ID: 16354245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies.
    Shetty S; Kusminski CM; Scherer PE
    Trends Pharmacol Sci; 2009 May; 30(5):234-9. PubMed ID: 19359049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease.
    Lara-Castro C; Fu Y; Chung BH; Garvey WT
    Curr Opin Lipidol; 2007 Jun; 18(3):263-70. PubMed ID: 17495599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of adiponectin in metabolic and vascular disease: a review.
    Cui J; Panse S; Falkner B
    Clin Nephrol; 2011 Jan; 75(1):26-33. PubMed ID: 21176748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases.
    Yamauchi T; Kadowaki T
    Int J Obes (Lond); 2008 Dec; 32 Suppl 7():S13-8. PubMed ID: 19136982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adiponectin: linking the metabolic syndrome to its cardiovascular consequences.
    Rabin KR; Kamari Y; Avni I; Grossman E; Sharabi Y
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):465-71. PubMed ID: 15889974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disorders in high-density metabolism with insulin resistance and chronic kidney disease.
    Kaysen GA
    J Ren Nutr; 2007 Jan; 17(1):4-8. PubMed ID: 17198924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Insulin resistance and inflammation in chronic kidney diseases].
    Guebre-Egziabher F; Kalbacher E; Fouque D
    Nephrol Ther; 2009 Jul; 5 Suppl 5():S346-52. PubMed ID: 19761971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: Adiponectin: its role in kidney disease.
    Shen YY; Peake PW; Charlesworth JA
    Nephrology (Carlton); 2008 Dec; 13(6):528-34. PubMed ID: 19138207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adiponectin and cardiovascular disease: response to therapeutic interventions.
    Han SH; Quon MJ; Kim JA; Koh KK
    J Am Coll Cardiol; 2007 Feb; 49(5):531-8. PubMed ID: 17276175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin in patients with chronic kidney disease.
    Adamczak M; Chudek J; Wiecek A
    Semin Dial; 2009; 22(4):391-5. PubMed ID: 19708988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome.
    Trujillo ME; Scherer PE
    J Intern Med; 2005 Feb; 257(2):167-75. PubMed ID: 15656875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification.
    Johnson DW; Armstrong K; Campbell SB; Mudge DW; Hawley CM; Coombes JS; Prins JB; Isbel NM
    Nephrology (Carlton); 2007 Aug; 12(4):391-8. PubMed ID: 17635756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of inflammation to vascular disease in chronic kidney disease patients.
    Suliman ME; Stenvinkel P
    Saudi J Kidney Dis Transpl; 2008 May; 19(3):329-45. PubMed ID: 18445891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease.
    Hajer GR; van der Graaf Y; Olijhoek JK; Edlinger M; Visseren FL
    Am Heart J; 2007 Oct; 154(4):750.e1-7. PubMed ID: 17893004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights on inflammation in chronic kidney disease-genetic and non-genetic factors.
    Stenvinkel P
    Nephrol Ther; 2006 Jul; 2(3):111-9. PubMed ID: 16890135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation and adipose tissue in uremia.
    Barazzoni R; Biolo G; Zanetti M; Bernardi A; Guarnieri G
    J Ren Nutr; 2006 Jul; 16(3):204-7. PubMed ID: 16825020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin in renal disease--a review of the evidence as a risk factor for cardiovascular and all-cause mortality.
    Connelly PW; Ramesh Prasad GV
    Crit Rev Clin Lab Sci; 2012; 49(5-6):218-31. PubMed ID: 23216078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adiponectin: saving the starved and the overfed.
    Behre CJ
    Med Hypotheses; 2007; 69(6):1290-2. PubMed ID: 17509773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.